Takeda Posts Q2 Loss on Impairment Charges, Cuts FY22 Guidance

Takeda Pharmaceutical reported a net loss of ¥11.8bn ($77.3m) in Q2, compared to a net profit of ¥92.0bn in the same period last year. The company recorded impairment charges of around ¥58bn due to discontinued drug research. Takeda cut its FY22 revenue guidance to a 1.8% decline to ¥4.5tn and raised its net profit forecast by 42% to ¥153.0bn.